Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SDCBP | O00560 | 12/20 | 0.43 |
| ▸ | SDC2 | P34741 | 12/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | XIAP | P98170 | 1/20 | 0.36 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | STAT3 | P40763 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18765566 | 1.00 | SDCBP (0.43) | SDCBPSDC2ALOX15MAPTSMN1; SMN2 | |
| SCHEMBL23309934 | 0.91 | NPC1 (0.45) | SDCBPSDC2ALOX15MAPTSMN1; SMN2 | |
| SCHEMBL23309933 | 0.91 | NPC1 (0.45) | SDCBPSDC2ALOX15MAPTSMN1; SMN2 | |
| SCHEMBL2181188 | 0.83 | ALOX15 (0.47) | SDCBPSDC2ALOX15MAPTSMN1; SMN2 | |
| SCHEMBL18765787 | 0.81 | ALOX15 (0.37) | SDCBPSDC2ALOX15MAPTSMN1; SMN2 | |
| SCHEMBL20720256 | 0.81 | ALOX15 (0.37) | SDCBPSDC2ALOX15MAPTSMN1; SMN2 | |
| SCHEMBL18765805 | 0.79 | ALOX15 (0.50) | SDCBPSDC2ALOX15MAPTSMN1; SMN2 | |
| SCHEMBL18765807 | 0.79 | ALOX15 (0.50) | SDCBPSDC2ALOX15MAPTSMN1; SMN2 | |
| SCHEMBL18766115 | 0.78 | MAPK1 (0.49) | — | |
| SCHEMBL18766071 | 0.78 | MAPK1 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3365334-B1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-11939321-B2 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-03-26 | — | — | US | disclosed |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| US-10457669-B2 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-10-29 | — | — | US | disclosed |
| US-20190047990-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11939321-B2 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | SDCBP 4427/4885SDC2 4003/4885ALOX15 1370/4885 |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | SDCBP 4427/4885SDC2 4003/4885ALOX15 1370/4885 |
| US-20190047990-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | SDCBP 4427/4885SDC2 4003/4885ALOX15 1370/4885 |
| US-10457669-B2 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | SDCBP 4427/4885SDC2 4003/4885ALOX15 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.